EYEN - Eyenovia

-

$undefined

N/A

(N/A)

Eyenovia NasdaqCM:EYEN Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Location: 295 Madison Avenue, New York, NY, 10017, United States | Website: https://www.eyenovia.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.43M

Cash

3.935M

Avg Qtr Burn

-6.168M

Short % of Float

2.06%

Insider Ownership

0.75%

Institutional Own.

9.71%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.